PL354604A1 - Sposób otrzymywania amorficznej soli wapniowej atorwastatyny - Google Patents
Sposób otrzymywania amorficznej soli wapniowej atorwastatynyInfo
- Publication number
- PL354604A1 PL354604A1 PL00354604A PL35460400A PL354604A1 PL 354604 A1 PL354604 A1 PL 354604A1 PL 00354604 A PL00354604 A PL 00354604A PL 35460400 A PL35460400 A PL 35460400A PL 354604 A1 PL354604 A1 PL 354604A1
- Authority
- PL
- Poland
- Prior art keywords
- atorvastatin calcium
- amorphous atorvastatin
- preparation
- amorphous
- crude
- Prior art date
Links
- OJRHUICOVVSGSY-RXMQYKEDSA-N (2s)-2-chloro-3-methylbutan-1-ol Chemical compound CC(C)[C@H](Cl)CO OJRHUICOVVSGSY-RXMQYKEDSA-N 0.000 title abstract 5
- 229960001770 atorvastatin calcium Drugs 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 2
- 238000002360 preparation method Methods 0.000 title abstract 2
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 abstract 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 abstract 1
- 208000035150 Hypercholesterolemia Diseases 0.000 abstract 1
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract 1
- 229960005370 atorvastatin Drugs 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 238000001816 cooling Methods 0.000 abstract 1
- 238000010438 heat treatment Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000003960 organic solvent Substances 0.000 abstract 1
- 238000001953 recrystallisation Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pyrrole Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU9903634A HU226640B1 (en) | 1999-10-18 | 1999-10-18 | Process for producing amorphous atorvastatin calcium salt |
| PCT/HU2000/000106 WO2001028999A1 (en) | 1999-10-18 | 2000-10-17 | Process for the preparation of amorphous atorvastatin calcium |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL354604A1 true PL354604A1 (pl) | 2004-01-26 |
Family
ID=90014241
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL00354604A PL354604A1 (pl) | 1999-10-18 | 2000-10-17 | Sposób otrzymywania amorficznej soli wapniowej atorwastatyny |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP1235800B1 (pl) |
| JP (1) | JP2003512354A (pl) |
| KR (1) | KR100664353B1 (pl) |
| CN (1) | CN1157374C (pl) |
| AT (1) | ATE345327T1 (pl) |
| AU (1) | AU1166301A (pl) |
| CA (1) | CA2388018C (pl) |
| CZ (1) | CZ300071B6 (pl) |
| DE (1) | DE60031882T2 (pl) |
| HK (1) | HK1050199A1 (pl) |
| HR (1) | HRP20020334B1 (pl) |
| HU (1) | HU226640B1 (pl) |
| PL (1) | PL354604A1 (pl) |
| RS (1) | RS50473B (pl) |
| RU (1) | RU2255932C2 (pl) |
| SK (1) | SK286861B6 (pl) |
| UA (1) | UA72777C2 (pl) |
| WO (1) | WO2001028999A1 (pl) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7411075B1 (en) | 2000-11-16 | 2008-08-12 | Teva Pharmaceutical Industries Ltd. | Polymorphic form of atorvastatin calcium |
| SI20425A (sl) * | 1999-12-10 | 2001-06-30 | LEK tovarna farmacevtskih in kemi�nih izdelkov d.d. | Priprava amorfnega atorvastatina |
| US7501450B2 (en) | 2000-11-30 | 2009-03-10 | Teva Pharaceutical Industries Ltd. | Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms |
| IL156055A0 (en) | 2000-11-30 | 2003-12-23 | Teva Pharma | Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms |
| WO2002057229A1 (en) | 2001-01-19 | 2002-07-25 | Biocon India Limited | FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN) |
| DE10135493A1 (de) * | 2001-07-20 | 2003-01-30 | Jobst Krauskopf | Pharmazeutische Zusammensetzung zur Behandlung von Hypercholesterinämie |
| EP1414796A1 (en) | 2001-07-30 | 2004-05-06 | Dr. Reddy's Laboratories Ltd. | Crystalline forms vi and vii of atorvastatin calcium |
| ATE452871T1 (de) * | 2002-03-18 | 2010-01-15 | Biocon Ltd | Amorphe hmg-coa-reduktase-inhibitoren mit gewünschter teilchengrösse |
| ITMI20020907A1 (it) * | 2002-04-29 | 2003-10-29 | Chemi Spa | Processo di preparazione della forma amorfa del sale di calcio della atorvastatina |
| WO2003099785A1 (en) * | 2002-05-28 | 2003-12-04 | Cadila Healthcare Limited | Process for the preparation of amorphous atorvastatin calcium |
| HU227041B1 (en) * | 2003-03-24 | 2010-05-28 | Richter Gedeon Nyrt | Process for the synthesis of amorphous atorvastatin calcium |
| US7790197B2 (en) | 2003-06-09 | 2010-09-07 | Warner-Lambert Company Llc | Pharmaceutical compositions of atorvastatin |
| US20050271717A1 (en) | 2003-06-12 | 2005-12-08 | Alfred Berchielli | Pharmaceutical compositions of atorvastatin |
| US7655692B2 (en) | 2003-06-12 | 2010-02-02 | Pfizer Inc. | Process for forming amorphous atorvastatin |
| CZ298382B6 (cs) * | 2004-03-10 | 2007-09-12 | Zentiva, A. S. | Zpusob prípravy amorfní formy hemivápenaté soli atorvastatinu a její stabilizace |
| EP1577297A1 (en) | 2004-03-17 | 2005-09-21 | Ranbaxy Laboratories, Ltd. | Process for the production of atorvastatin calcium in amorphous form |
| RU2330840C1 (ru) * | 2004-04-16 | 2008-08-10 | Пфайзер Продактс Инк. | Способ получения аморфного кальций аторвастатина |
| CN1692906A (zh) * | 2004-04-30 | 2005-11-09 | 鲁南制药集团股份有限公司 | 治疗高血脂症的组合物 |
| ES2739493T3 (es) | 2004-05-05 | 2020-01-31 | Pfizer Prod Inc | Formas de sal de de atorvastatina con benetamina |
| CA2672554C (en) | 2004-07-20 | 2012-01-03 | Warner-Lambert Company Llc | Novel forms of [r-(r*,r*)]-2-(4-fluorophenyl).beta.,.delta.-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1) |
| CN101124230A (zh) * | 2004-09-28 | 2008-02-13 | 特瓦制药工业有限公司 | 制备基本无杂质的阿托伐他汀钙形式的方法 |
| TW200942516A (en) * | 2004-10-18 | 2009-10-16 | Teva Pharma | Processes for preparing amorphous atorvastatin hemi-calcium |
| AU2005298383A1 (en) | 2004-10-28 | 2006-05-04 | Warner-Lambert Company Llc | Process for forming amorphous atorvastatin |
| DE602006014193D1 (de) | 2005-11-21 | 2010-06-17 | Warner Lambert Co | Neue formen von är-(r*,r*)ü-2-(4-fluorphenyl)-b,d-dihydroxy-5-(1-methylethyl)-3-phenyl-4-ä(phenylamino)carbonylü-1h-pyrrol-1-heptansäure-magnesium |
| EP1810667A1 (en) | 2006-01-20 | 2007-07-25 | KRKA, tovarna zdravil, d.d., Novo mesto | Pharmaceutical composition comprising amorphous atorvastatin |
| KR100833439B1 (ko) * | 2007-01-02 | 2008-05-29 | 씨제이제일제당 (주) | 비결정형 아토르바스타틴 칼슘의 개선된 제조방법 |
| CZ201039A3 (cs) | 2010-01-19 | 2011-07-27 | Zentiva, K. S | Zpusob prumyslové výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu) s vysokým specifickým povrchem a jeho použití v lékové forme |
| HUP1000299A2 (hu) | 2010-06-08 | 2012-02-28 | Nanoform Cardiovascular Therapeutics Ltd | Nanostrukturált Atorvastatint, gyógyszerészetileg elfogadott sóit és kokristályait tartalmazó készítmény és eljárás elõállításukra |
| CN102424663B (zh) * | 2010-12-03 | 2013-08-14 | 天津滨江药物研发有限公司 | 一种阿托伐他汀氨基酸盐及其制备方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI94339C (fi) * | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
| HRP960312B1 (en) * | 1995-07-17 | 2001-10-31 | Warner Lambert Co | NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS /R-(R*, R*)/-2-(4-FLUOROPHENYL)-"beta", "delta"-DIHYDROXY-5-PHENYL-4-/(PHENYLAMINO)CARBONYL/-1H-PYRROLE -1-HEPTANOIC ACID CALCIUM SALT (2 : 1) |
| CN1116299C (zh) * | 1996-09-20 | 2003-07-30 | 明治制果株式会社 | 头孢地托伦新戊酰氧甲酯晶体及其生产方法 |
-
1999
- 1999-10-18 HU HU9903634A patent/HU226640B1/hu not_active IP Right Cessation
-
2000
- 2000-10-17 PL PL00354604A patent/PL354604A1/pl not_active Application Discontinuation
- 2000-10-17 EP EP00973115A patent/EP1235800B1/en not_active Expired - Lifetime
- 2000-10-17 CN CNB008144583A patent/CN1157374C/zh not_active Expired - Fee Related
- 2000-10-17 AU AU11663/01A patent/AU1166301A/en not_active Abandoned
- 2000-10-17 RU RU2002113564/04A patent/RU2255932C2/ru not_active IP Right Cessation
- 2000-10-17 SK SK519-2002A patent/SK286861B6/sk not_active IP Right Cessation
- 2000-10-17 DE DE60031882T patent/DE60031882T2/de not_active Expired - Fee Related
- 2000-10-17 JP JP2001531799A patent/JP2003512354A/ja active Pending
- 2000-10-17 CA CA002388018A patent/CA2388018C/en not_active Expired - Fee Related
- 2000-10-17 AT AT00973115T patent/ATE345327T1/de not_active IP Right Cessation
- 2000-10-17 KR KR1020027004906A patent/KR100664353B1/ko not_active IP Right Cessation
- 2000-10-17 UA UA2002054059A patent/UA72777C2/uk unknown
- 2000-10-17 WO PCT/HU2000/000106 patent/WO2001028999A1/en active IP Right Grant
- 2000-10-17 CZ CZ20021256A patent/CZ300071B6/cs not_active IP Right Cessation
- 2000-10-17 RS YUP-283/02A patent/RS50473B/sr unknown
-
2002
- 2002-04-15 HR HR20020334A patent/HRP20020334B1/xx not_active IP Right Cessation
-
2003
- 2003-04-04 HK HK03102420A patent/HK1050199A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| HUP9903634A2 (hu) | 2001-12-28 |
| CA2388018A1 (en) | 2001-04-26 |
| DE60031882D1 (de) | 2006-12-28 |
| HRP20020334A2 (en) | 2004-02-29 |
| KR100664353B1 (ko) | 2007-01-02 |
| JP2003512354A (ja) | 2003-04-02 |
| AU1166301A (en) | 2001-04-30 |
| CA2388018C (en) | 2008-04-08 |
| HU226640B1 (en) | 2009-05-28 |
| UA72777C2 (en) | 2005-04-15 |
| HUP9903634D0 (en) | 1999-12-28 |
| EP1235800B1 (en) | 2006-11-15 |
| DE60031882T2 (de) | 2007-07-05 |
| WO2001028999A1 (en) | 2001-04-26 |
| RS50473B (sr) | 2010-03-02 |
| CN1157374C (zh) | 2004-07-14 |
| KR20020063166A (ko) | 2002-08-01 |
| CZ300071B6 (cs) | 2009-01-21 |
| HUP9903634A3 (en) | 2002-01-28 |
| YU28302A (sh) | 2005-06-10 |
| EP1235800A1 (en) | 2002-09-04 |
| CN1379760A (zh) | 2002-11-13 |
| RU2255932C2 (ru) | 2005-07-10 |
| SK5192002A3 (en) | 2002-11-06 |
| ATE345327T1 (de) | 2006-12-15 |
| HK1050199A1 (en) | 2003-06-13 |
| CZ20021256A3 (cs) | 2002-08-14 |
| HRP20020334B1 (en) | 2007-12-31 |
| SK286861B6 (sk) | 2009-06-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1050199A1 (en) | Process for the preparation of amorphous atorvastatin calcium. | |
| Short et al. | A solid-phase combinatorial method for the synthesis of novel 5-and 6-membered ring lactams | |
| HK1045118A1 (zh) | 無定形的阿伐他汀鈣的製備方法 | |
| CA2172616C (en) | Tropyl 7-azaindol-3-ylcarboxyamides as antitussive agent | |
| ATE243672T1 (de) | Neue thyroid-rezeptorliganden und verfahren | |
| AU5598398A (en) | Pyrroles as sPLA2 inhibitors | |
| JP2003512354A5 (pl) | ||
| SE1102739T5 (pl) | ||
| GR3025420T3 (en) | Process for solid support nucleic acid synthesis and compounds useful as solid supports in said process | |
| US6646133B1 (en) | Process for the preparation of amorphous atorvastatin calcium | |
| AU668161B2 (en) | Novel process and intermediates | |
| Bartrum et al. | Synthesis of β2-homophenylalanine derivatives by Negishi cross-coupling reactions | |
| TW358826B (en) | Compatibilized polymer blends formed using a multifunctional agent | |
| Delle Monache et al. | Iodolactonization of 3-amino-4-pentenoic acid: a stereoselective synthesis of syn-γ-hydroxy-β-amino acids | |
| Cho et al. | SYNTHESIS OF 3-SUBST1: TUTED 3, 4-DIHYDROPYRIMIDINES: g-ALXOXY-CARBONYLATION WITH TILICHLOROMETHYL CHLOROFORMATE AND ALCOHOLS | |
| LluisaáBennasar | A new synthetic entry to the alkaloids of the mavacurine group. First total synthesis of (▒)-2, 7-dihydropleiocarpamine | |
| NO129524B (pl) | ||
| US20040063969A1 (en) | Process for the preparation of amorphous atorvastatin calcium | |
| Pernfa | Stabilisation of a Cis Amide Bond in a Host-Guest Complex. Glen J. Pernfa, Jeremy D. Kilburn, Jonathan W. Essex, Russell J. Mortishire-Smith, and Michael Rowley | |
| PL177187B1 (pl) | 2,3,4,3’,4’-penta -O-benzylo-sacharoza i sposób jej otrzymywania |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| REFS | Decisions on refusal to grant patents (taken after the publication of the particulars of the applications) |